Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. with a P/E of 4.74. Additionally, Protalix's EV to EBITDA ratio stands at 15.52, while its peers are demonstrating much lower ratios, suggesting a premium valuation relative to the industry.
In comparison to its peers, Protalix Biotherapeutics shows a ROCE of 38.92% and a ROE of 8.64%, which are strong indicators of operational efficiency but do not justify its current valuation levels when compared to peers like Puma Biotechnology, which is classified as very attractive. The stock's recent performance against the S&P 500 is not available, but the current valuation metrics suggest that investors may want to exercise caution before investing at this price level.